IDEXX Laboratories, Inc. (IDXX) $576.07
IDEXX is currently caught in a technical purgatory, trading 25% below its yearly highs while institutional support levels face a critical test ahead of August earnings.
52-wk High $769.98
📌 Investment Snapshot
- Trading at $576.07 with a premium P/E of 42.4x despite being 25% off 52-week highs.
- Q1 2026 revenue reached $1.14B with EPS of $3.50, showing steady sequential growth.
- Pet healthcare spending remains resilient, but high interest rates pressure clinical CAPEX.
- Analyst consensus points to $708.43, implying significant double-digit recovery potential.
⏳ WAIT
IDEXX is showing signs of a bottom after a buy-side liquidity sweep at $547.38. However, the stock remains pinned below its SMA200 and Anchored VWAP, suggesting the path of least resistance is still sideways.
| 📍 Entry Zone | $555 or below | 🛑 Stop-Loss | $510 |
| 📋 Adjust If | Earnings on Aug 4th show a margin contraction below 29%. | ||
The Investment Case — Why Now?
Over the last 90 days, IDEXX has transitioned from a momentum darling to a value-discovery play within the veterinary diagnostics space. While the 3-month return of -2.2% looks bleak, the recent +3.29% daily pop suggests buyers are finally defending the $550 psychological floor. This stabilization comes as institutional heavyweights like Blackrock and Vanguard maintain massive positions totaling over 13 million shares.
The primary risk centers on the 10Y Treasury yield sitting at 4.57%, which continues to compress the valuation multiples of high-growth healthcare stocks. With a P/E of 42.4x, IDEXX is not ‘cheap’ by traditional standards and could see another 10% leg down if the August 4th earnings guidance underwhelms. Can IDEXX justify its 42x multiple if clinical instrument placements slow down in a high-rate environment?
We are staying on the sidelines until the stock reclaims the SMA50 at $555.05 with conviction. A successful retest of the $563 Point of Control (POC) would confirm that the ‘smart money’ is ready to rotate back into the sector.
🤔 Can IDEXX justify its 42x multiple if clinical instrument placements slow down in a high-rate environment?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Employees | 11,000+ |
| Headquarters | Westbrook, Maine |
Open chart on TradingView →
📈 Price Action & Technicals
Golden Cross
Inside VA
Buy-side Sweep at $547.38 on 2026-07-14
The price action is currently sandwiched between the SMA50 ($555.05) and the SMA200 ($624.46), indicating a lack of long-term trend direction. While the recent golden cross in the MACD signals a short-term bullish shift, the ADX at 10.2 confirms this is a weak trend with little follow-through volume.
RSI at 56.8 shows that the stock has moved out of the ‘value’ zone but hasn’t yet reached the ‘overbought’ territory that would trigger a sell. This neutral reading suggests the market is waiting for a fundamental catalyst, likely the upcoming August earnings report.
The Volume Profile Point of Control (POC) at $563.81 is acting as a magnet, with the stock currently hovering just above this high-volume node. This area represents the ‘fair value’ where most trading has occurred, making it a difficult level to break without significant news.
We observed a critical buy-side liquidity sweep at $547.38 on July 14th, which effectively cleared out weak-handed shorts and set a local floor. However, the stock remains significantly below its Anchored VWAP of $621.45, which continues to act as a ceiling for institutional recovery.
Historically, when IDXX trades this far below its SMA200 while maintaining positive EPS growth, it enters a 3-to-6 month consolidation phase. Expect choppy trading within the Bollinger Bands ($527.79 — $578.18) until the earnings volatility clears the air.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| IDXX | IDEXX Laboratories | 42.4x |
| ZTS | Zoetis Inc. | 34.2x |
| ZBH | Zimmer Biomet | 22.1x |
| SPY | S&P 500 Avg | 21.5x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $1.14B | $3.50 | +7.5% |
| Q4 2025 | $1.09B | $3.11 | +6.2% |
| Q3 2025 | $1.11B | $3.43 | +8.1% |
| Q2 2025 | $1.11B | $3.66 | +9.4% |
Latest quarterly Free Cash Flow stands at $0.2B, supported by a robust $0.4B buyback program that signals management’s confidence in the current valuation.
Revenue has remained remarkably stable around the $1.1B mark for four consecutive quarters, suggesting a plateau in organic growth. Investors should watch for a breakout in the Companion Animal Group (CAG) margins in the next report.
🚀 Growth Drivers — What Moves the Stock
- Cloud Software Expansion 🟢 Upside Surprise — Rapid adoption of ezyVet and Neo software is creating high-margin recurring revenue streams.
- International Lab Expansion 🟡 Priced In — New reference labs in Europe and Asia are scaling, though currency headwinds remain a factor.
🤔 Will the shift toward high-margin software be enough to offset the slowing hardware sales in 2026?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 8,365 |
| Vanguard Capital Management | 5,182 |
| State Street Corporation | 3,674 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| FENNELL GEORGE | Officer | 2026-06-01 | Sale | 639 |
| SZOSTAK MARGARET | Director | 2026-05-07 | Sale | 257 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 2.8% | 2.9 |
⚠ Key Risk Factors
~$1.2B valuation impact
~$200M revenue risk
🎯 Guidance & Wall Street View
Management expects full-year 2026 revenue growth in the 7-10% range, contingent on stable pet owner visit frequency.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $805.00 | $708.43 | $470.00 | 14 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| UBS | Neutral | null | 2026-04-28 | Maintained |
| Stifel | Buy | null | 2026-03-31 | Maintained |
While the consensus remains a ‘Buy’, recent ‘Neutral’ initiations from Citi and UBS suggest a cooling of analyst enthusiasm near-term.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Software-as-a-Service (SaaS) revenue grows to 25% of total mix.
- Successful launch of next-gen rapid assay tests in Q3.
📊 Base Case
IDEXX maintains steady 8% revenue growth and continues aggressive share buybacks.
🐻 Bear Case
- Pet clinic visits drop by 5% due to consumer spending fatigue.
- Margin compression as R&D costs for AI diagnostics spike.
🎯 Investor Action Plan — By Profile
The stock is currently testing the upper Bollinger Band at $578. Wait for a pullback to the $563 POC or a breakout above $585 with high volume before entering.
Maintain current holdings but avoid adding new capital until the stock reclaims the SMA200 at $624. The technical confluence score of 60 is not strong enough to justify a heavy buy.
For those with a 3-year horizon, the 25% discount from highs offers a reasonable entry point into a high-quality compounder with a dominant market share.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: When is the next IDEXX earnings date?
IDEXX is scheduled to report its next quarterly earnings on August 4, 2026.
Q: Is IDXX stock overvalued at a 42x P/E?
Historically, IDEXX has traded at a premium due to its recurring revenue model, but it is currently at the higher end of its peer group which includes Zoetis.
Q: What is the key technical level to watch for IDXX?
The most critical level is the SMA50 at $555.05; staying above this level is essential for maintaining the current short-term bullish momentum.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 How has the stock moved since this analysis?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. The author has no position in IDXX at the time of writing.
All active positions and their real-time performance are tracked on our Investment Log.
#IDXX #IDEXX #PetHealth #Diagnostics #StockMarket #Investing #HealthcareStocks